Literature DB >> 19554732

Modeling differential binding of alpha4beta2 nicotinic acetylcholine receptor with agonists and antagonists.

Xiaoqin Huang1, Fang Zheng, Chang-Guo Zhan.   

Abstract

Three-dimensional structures of both the open- and closed-channel states of alpha4beta2 receptor have been modeled and used to study their binding with representative agonists and antagonists. The obtained binding structures and free energies consistently reveal that antagonists bind more favorably with the closed-channel state and agonists bind more favorably with the open-channel state. The computational insights have led us to propose a computational strategy and protocol predicting whether a receptor ligand is an agonist or antagonist. Using the computational protocol, one only needs to calculate the relative binding free energies for a ligand binding with the open- and closed-channel structures. The ligand is predicted to be an agonist if the binding free energy calculated for the ligand binding with the open-channel state is significantly lower than that for its binding with the closed-channel state. If the binding free energy of a ligand with the open-channel state is higher than that with the closed-channel, the ligand is predicted to be an antagonist. The binding free energies calculated for all of the ligands binding with their most favorable channel states of the receptor are all close to the corresponding experimentally derived binding free energies. The new computational insights obtained and novel computational strategy and protocol proposed in this study are expected to be valuable in structure-based rational design of novel agonists/antagonists of nAChRs as therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19554732     DOI: 10.1021/ja8055326

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  7 in total

1.  Exploring the binding energy profiles of full agonists, partial agonists, and antagonists of the α7 nicotinic acetylcholine receptor.

Authors:  Nargis Tabassum; Qianyun Ma; Guanzhao Wu; Tao Jiang; Rilei Yu
Journal:  J Mol Model       Date:  2017-08-02       Impact factor: 1.810

2.  Phenylethynyl-substituted Heterocycles Inhibit Cyclin D1 and Induce the Expression of Cyclin-dependent Kinase Inhibitor p21Wif1/Cip1 in Colorectal Cancer Cells.

Authors:  Vitaliy M Sviripa; Liliia M Kril; Wen Zhang; Yanqi Xie; Przemyslaw Wyrebek; Larissa Ponomareva; Xifu Liu; Yaxia Yuan; Chang-Guo Zhan; David S Watt; Chunming Liu
Journal:  Medchemcomm       Date:  2017-11-03       Impact factor: 3.597

3.  Design, synthesis, and biological activity of 5'-phenyl-1,2,5,6-tetrahydro-3,3'-bipyridine analogues as potential antagonists of nicotinic acetylcholine receptors.

Authors:  Yafei Jin; Xiaoqin Huang; Roger L Papke; Emily M Jutkiewicz; Hollis D Showalter; Chang-Guo Zhan
Journal:  Bioorg Med Chem Lett       Date:  2017-08-14       Impact factor: 2.823

4.  First-Principles Determination of Molecular Conformations of Indolizidine (-)-235B' in Solution.

Authors:  Fang Zheng; Linda P Dwoskin; Peter A Crooks; Chang-Guo Zhan
Journal:  Theor Chem Acc       Date:  2009-10-01       Impact factor: 1.702

5.  QSAR study on maximal inhibition (Imax) of quaternary ammonium antagonists for S-(-)-nicotine-evoked dopamine release from dopaminergic nerve terminals in rat striatum.

Authors:  Fang Zheng; Matthew J McConnell; Chang-Guo Zhan; Linda P Dwoskin; Peter A Crooks
Journal:  Bioorg Med Chem       Date:  2009-05-08       Impact factor: 3.641

6.  Binding Modes and Selectivity of Cannabinoid 1 (CB1) and Cannabinoid 2 (CB2) Receptor Ligands.

Authors:  Jing-Fang Yang; Alexander H Williams; Narsimha R Penthala; Paul L Prather; Peter A Crooks; Chang-Guo Zhan
Journal:  ACS Chem Neurosci       Date:  2020-09-30       Impact factor: 4.418

7.  Fast Prediction of Binding Affinities of SARS-CoV-2 Spike Protein and Its Mutants with Antibodies through Intermolecular Interaction Modeling-Based Machine Learning.

Authors:  Alexander H Williams; Chang-Guo Zhan
Journal:  J Phys Chem B       Date:  2022-07-11       Impact factor: 3.466

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.